Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of the gut microbiota in early life: The impact of cystic fibrosis and antibiotic treatment
Maartje Kristensen, Sabine M. P. J. Prevaes, Gino Kalkman, et al.
Journal of Cystic Fibrosis (2020) Vol. 19, Iss. 4, pp. 553-561
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

The Gut-Lung Axis in Cystic Fibrosis
Courtney E. Price, George A. O’Toole
Journal of Bacteriology (2021) Vol. 203, Iss. 20
Open Access | Times Cited: 65
What Do We Know about the Microbiome in Cystic Fibrosis? Is There a Role for Probiotics and Prebiotics?
Josie van Dorst, Rachel Y. Tam, Chee Y. Ooi
Nutrients (2022) Vol. 14, Iss. 3, pp. 480-480
Open Access | Times Cited: 43
Cystic Fibrosis-Related Gut Dysbiosis: A Systematic Review
L.R. Caley, H. White, Marcus C. de Goffau, et al.
Digestive Diseases and Sciences (2023) Vol. 68, Iss. 5, pp. 1797-1814
Closed Access | Times Cited: 24
Intestinal Bacteroides modulates inflammation, systemic cytokines, and microbial ecology via propionate in a mouse model of cystic fibrosis
Courtney E. Price, Rebecca A. Valls, Alexis R. Ramsey, et al.
mBio (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 14
The longitudinal microbial and metabolic landscape of infant cystic fibrosis: the gut–lung axis
Katherine B. Frayman, Matthew Macowan, José A. Caparrós‐Martín, et al.
European Respiratory Journal (2024) Vol. 63, Iss. 5, pp. 2302290-2302290
Closed Access | Times Cited: 8
Impact of Altered Gut Microbiota and Its Metabolites in Cystic Fibrosis
Aravind Thavamani, Iman Salem, Thomas J. Sferra, et al.
Metabolites (2021) Vol. 11, Iss. 2, pp. 123-123
Open Access | Times Cited: 43
Intestinal Inflammation and Alterations in the Gut Microbiota in Cystic Fibrosis: A Review of the Current Evidence, Pathophysiology and Future Directions
Rachel Y. Tam, Josie van Dorst, Isabelle McKay, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 3, pp. 649-649
Open Access | Times Cited: 31
Nisin probiotic prevents inflammatory bone loss while promoting reparative proliferation and a healthy microbiome
Li Gao, Ryutaro Kuraji, Martin Jinye Zhang, et al.
npj Biofilms and Microbiomes (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 26
Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome
Ryan Marsh, Claudio Dos Santos, Liam Hanson, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 5
Open Access | Times Cited: 15
Development of the intestinal microbiome in cystic fibrosis in early life
Courtney E. Price, Thomas H. Hampton, Rebecca Valls, et al.
mSphere (2023) Vol. 8, Iss. 4
Open Access | Times Cited: 13
Effects of Therapeutic Antibiotic Exposure on the Oropharyngeal and Fecal Microbiota in Infants With Cystic Fibrosis
Hillary S. Hayden, Maria T. Nelson, Sydney E. Ross, et al.
Pediatric Pulmonology (2025) Vol. 60, Iss. 3
Open Access
Effectiveness of Probiotics, Prebiotics, and Symbiotic Supplementation in Cystic Fibrosis Patients: A Systematic Review and Meta-Analysis of Clinical Trials
Freiser Eceomo Cruz Mosquera, Claudia Lorena Perlaza, Anisbed Naranjo Rojas, et al.
Medicina (2025) Vol. 61, Iss. 3, pp. 489-489
Open Access
Diet and the gut-lung axis in cystic fibrosis – direct & indirect links
Isabelle McKay, Josie van Dorst, Tamarah Katz, et al.
Gut Microbes (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 20
Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor
Seth A. Reasoner, Rachel Bernard, Adam Waalkes, et al.
mBio (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 4
Respiratory diseases and gut microbiota: relevance, pathogenesis, and treatment
Mengdi Sun, Fang Lü, Donghua Yu, et al.
Frontiers in Microbiology (2024) Vol. 15
Open Access | Times Cited: 4
The Prevalence of Polyketide Synthase-Positive E. coli in Cystic Fibrosis
Christopher Chan, Michael J. Coffey, Caitlin Murphy, et al.
Microorganisms (2025) Vol. 13, Iss. 3, pp. 681-681
Open Access
Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis
Ryan Marsh, Helen Gavillet, Liam Hanson, et al.
Journal of Cystic Fibrosis (2021) Vol. 21, Iss. 3, pp. 506-513
Open Access | Times Cited: 24
Thinking outside the box: a review of gastrointestinal symptoms and complications in cystic fibrosis
Alexander Yule, D. Sills, Sherie Smith, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 7, pp. 547-561
Open Access | Times Cited: 10
Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis
Ryan Marsh, Claudio Dos Santos, Alexander Yule, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 5, pp. 967-976
Open Access | Times Cited: 3
Probiotics Administration in Cystic Fibrosis: What Is the Evidence?
Susanna Esposito, Ilaria Testa, Elena Mariotti Zani, et al.
Nutrients (2022) Vol. 14, Iss. 15, pp. 3160-3160
Open Access | Times Cited: 13
An in vitro medium for modeling gut dysbiosis associated with cystic fibrosis
Kaitlyn E. Barrack, Thomas H. Hampton, Rebecca A. Valls, et al.
Journal of Bacteriology (2024) Vol. 206, Iss. 1
Open Access | Times Cited: 2
Regulation effect of the intestinal flora and intervention strategies targeting the intestinal flora in alleviation of pulmonary fibrosis development
Jianquan GUO, Liyang YANG
Bioscience of Microbiota Food and Health (2024) Vol. 43, Iss. 4, pp. 293-299
Open Access | Times Cited: 2
A New Insight into Phage Combination Therapeutic Approaches Against Drug-Resistant Mixed Bacterial Infections
Mohammadreza Rahimian, Davoud Jafari-Gharabaghlou, Elham Mohammadi, et al.
PHAGE (2024) Vol. 5, Iss. 4, pp. 203-222
Closed Access | Times Cited: 2
Lung-Directed Bacteriotherapy in Cystic Fibrosis: Could It Be an Option?
Giovanna Batoni, Giuseppantonio Maisetta, Esingül Kaya, et al.
Antibiotics (2022) Vol. 11, Iss. 3, pp. 326-326
Open Access | Times Cited: 12
Can Bioactive Food Substances Contribute to Cystic Fibrosis-Related Cardiovascular Disease Prevention?
Laura Mihaela Trandafir, Otilia Elena Frăsinariu, Elena Ţarcă, et al.
Nutrients (2023) Vol. 15, Iss. 2, pp. 314-314
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top